Global Clinical Mass Spectrometry Revenue Is Nearly 723.71 M USD In 2018
Friday, 15 Nov, 2019
Mass spectrometry is an analytic technique with high specificity and a growing presence in laboratory medicine. Various types of mass spectrometers are being used in an increasing number of clinical laboratories around the world, and, as a result, significant improvements in assay performance are occurring rapidly in areas such as toxicology, endocrinology, and biochemical genetics.
Clinical mass spectrometry uses the mass spectrometry technology for diagnostic purposes. Employed by medical labs, clinical mass spectrometry is used to diagnose metabolism deficiencies, to determine whether biomarkers or enzymes are present, and for toxicology testing.
In the last several years, global market of Clinical Mass Spectrometry developed with an average growth rate of 12.08%. In 2018, global revenue of Clinical Mass Spectrometry is nearly 723.71 M USD; the actual sales are about 2446 Unit.
The global average price of Clinical Mass Spectrometry is in the stable and decreasing trend, from 300.1 K USD/Unit in 2014 to 295.9 K USD/Unit in 2018. With the situation of global economy, prices will be in stable and decreasing trend in the following years.
The classification of Clinical Mass Spectrometry includes LC-MS, GC-MS and others. The proportion of LC-MS in 2018 is about 79.72%, and the proportion is in decreasing trend from 2013 to 2018.
Clinical Mass Spectrometry is widely used for clinical diagnostic and clinical research. The most proportion of Clinical Mass Spectrometry is in clinical research, and the proportion in 2018 is 73.43%.
North America is the largest consumer of Clinical Mass Spectrometry, with a sales market share nearly 44.11% in 2018. Europe is the second largest consumer of Clinical Mass Spectrometry, enjoying sales market share nearly 32.52% in 2018.
Market competition is intense. AB Sciex (Danaher), Bruker, Thermo Fisher, Agilent, Waters, Perkin Elmer and Shidmazu are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.